Tags

Type your tag names separated by a space and hit enter

Statin-Associated Muscle Disease: Advances in Diagnosis and Management.
Neurotherapeutics. 2018 10; 15(4):1006-1017.N

Abstract

Since the first approval of lovastatin in 1987, hydroxy-methyl-glutaryl CoA (HMG CoA) reductase inhibitors, or statins, have been effective and widely popular cholesterol-lowering agents with substantial benefits for the prevention and treatment of cardiovascular disease. Not all patients can tolerate these drugs, however, and statin intolerance is most frequently associated with a range of side effects directed toward skeletal muscle, termed statin-associated muscle symptoms or SAMS. SAMS are particularly difficult to treat because there are no validated biomarkers or tests that can be used to confirm patient self-reports of SAMS, and a number of patients who report SAMS have non-specific muscle pain not attributable to statin therapy. This review summarizes the most recent evidence related to diagnosis and management of SAMS. First, the range of skeletal muscle side effects associated with statin therapy is described. Second, data regarding the incidence and prevalence of SAMS, the most frequently experienced muscle side effect, are presented. Third, the most promising new techniques to confirm diagnosis of SAMS are explored. Finally, the most effective strategies for the clinical management of SAMS are summarized. Better diagnostic and treatment strategies for SAMS will increase the number of patients using these life-saving statins, thereby increasing statin adherence and reducing the costs of avoidable cardiovascular events.

Authors+Show Affiliations

Division of Cardiology, Hartford Healthcare, Hartford, CT, USA. Beth.Taylor@uconn.edu. Department of Kinesiology, University of Connecticut, Storrs, CT, USA. Beth.Taylor@uconn.edu. University of Connecticut School of Medicine, Farmington, CT, USA. Beth.Taylor@uconn.edu.Division of Cardiology, Hartford Healthcare, Hartford, CT, USA. University of Connecticut School of Medicine, Farmington, CT, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30251222

Citation

Taylor, Beth A., and Paul D. Thompson. "Statin-Associated Muscle Disease: Advances in Diagnosis and Management." Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics, vol. 15, no. 4, 2018, pp. 1006-1017.
Taylor BA, Thompson PD. Statin-Associated Muscle Disease: Advances in Diagnosis and Management. Neurotherapeutics. 2018;15(4):1006-1017.
Taylor, B. A., & Thompson, P. D. (2018). Statin-Associated Muscle Disease: Advances in Diagnosis and Management. Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics, 15(4), 1006-1017. https://doi.org/10.1007/s13311-018-0670-z
Taylor BA, Thompson PD. Statin-Associated Muscle Disease: Advances in Diagnosis and Management. Neurotherapeutics. 2018;15(4):1006-1017. PubMed PMID: 30251222.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Statin-Associated Muscle Disease: Advances in Diagnosis and Management. AU - Taylor,Beth A, AU - Thompson,Paul D, PY - 2018/9/27/pubmed PY - 2019/3/13/medline PY - 2018/9/26/entrez KW - Myalgia KW - Skeletal muscle KW - Statin intolerance KW - Statin-associated muscle symptoms KW - Statins SP - 1006 EP - 1017 JF - Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics JO - Neurotherapeutics VL - 15 IS - 4 N2 - Since the first approval of lovastatin in 1987, hydroxy-methyl-glutaryl CoA (HMG CoA) reductase inhibitors, or statins, have been effective and widely popular cholesterol-lowering agents with substantial benefits for the prevention and treatment of cardiovascular disease. Not all patients can tolerate these drugs, however, and statin intolerance is most frequently associated with a range of side effects directed toward skeletal muscle, termed statin-associated muscle symptoms or SAMS. SAMS are particularly difficult to treat because there are no validated biomarkers or tests that can be used to confirm patient self-reports of SAMS, and a number of patients who report SAMS have non-specific muscle pain not attributable to statin therapy. This review summarizes the most recent evidence related to diagnosis and management of SAMS. First, the range of skeletal muscle side effects associated with statin therapy is described. Second, data regarding the incidence and prevalence of SAMS, the most frequently experienced muscle side effect, are presented. Third, the most promising new techniques to confirm diagnosis of SAMS are explored. Finally, the most effective strategies for the clinical management of SAMS are summarized. Better diagnostic and treatment strategies for SAMS will increase the number of patients using these life-saving statins, thereby increasing statin adherence and reducing the costs of avoidable cardiovascular events. SN - 1878-7479 UR - https://www.unboundmedicine.com/medline/citation/30251222/Statin_Associated_Muscle_Disease:_Advances_in_Diagnosis_and_Management_ L2 - https://dx.doi.org/10.1007/s13311-018-0670-z DB - PRIME DP - Unbound Medicine ER -